About the best thing I can say about my bullish call(s) on Agilent (NYSE:A) is that owning its shares hasn't hurt you too badly in 2012, as the stock has lagged the S&P 500 by about 7% for the year so far and actually outperformed (slightly) over the past quarter. While the company's guidance for 2013 was not very compelling, I continue to believe that Agilent offers a good collection of businesses with ongoing growth potential, as well as longer-term margin and free cash flow (FCF) leverage. The question is whether or not investors can afford to be patient while that long-term thesis works itself out.

Forex Broker Guide: Using the right broker is essential when competing in today's forex marketplace.

Ending the Year on a Good Note ...
Despite relative sluggish performance from a variety of comps including Danaher (NYSE:DHR) and Life Technologies (Nasdaq:LIFE), Agilent basically got the job done for its fiscal fourth quarter. Revenue rose 2% as reported, but declined 1% on an organic basis. Electronic Measurement was the underperformer again, as revenue fell 5% on a continued slowdown in communications. Chemical Analysis declined 3% from last year, helped by an increase in sales to the forensics market. Life Sciences ended the quarter flat, while Diagnostics and Genomics rose 1% on an organic basis.

Margin performance was pretty solid at Agilent. On an adjusted basis, the company reported better than a half-point improvement in gross margin, while adjusted operating income rose 2% and the company squeaked out a higher operating margin despite increased SG&A and R&D spending.

... Sort of
Although Agilent's quarter came in pretty solid relative to expectations, the company's order trends and guidance were not as encouraging.

Orders declined 3% on an organic basis, with an 8% drop in EMG orders leading the way down. Only the D&G group saw a year-on-year improvement, though Life Sciences and CA did improve on a sequential basis and the book-to-bill improved slightly as well.

Agilent management has something of a reputation for conservative (or at least credible) guidance, so its comments after this quarter were a bit concerning. For the year ahead, it is looking for organic revenue growth of just 1.5%, with higher compensation expense pointing to an EPS target about 12% lower than the prior average analyst estimate. Keep in mind, too, that that assumes that the fiscal cliff issues get resolved and that China recovers later in the year, so there's arguably still some risk in those numbers.

SEE: Can Earnings Guidance Accurately Predict The Future?

Still a When, not if, Story?
2013 is increasingly looking like a tough, muddle-through sort of year. Said differently, if 2013 ends up being strong, it will come as a surprise to the managers of companies such as Danaher, Illinois Tool Works (NYSE:ITW), Dover (NYSE:DOV) and Life Tech.

For Agilent in particular, a recovery in the semiconductor industry would be a big help, as would a pick up in carrier telecom equipment spending. While I don't see government research budgets swelling (bad news for Life Tech and Illumina (Nasdaq:ILMN) as well), Agilent's more significant leverage to markets such as pharmaceuticals, energy, forensics and food/beverage should help offset that to some degree. On the diagnostics side, I think Agilent investors need to continue to look at Dako as a long-term fix-er-up opportunity on par with Danaher's acquisition of Beckman; in other words, Dako won't save the day in 2013.

All of that said, I continue to believe Agilent is in the right markets for long-term growth. Electronic test and measurement is a cyclical industry, but one that should continue to cycle upwards. While Chemical Analysis, Life Sciences, and Diagnostics may be a little more sedate, I do believe they'll provide above average long-term growth and margins that will be quite beneficial to Agilent's cash flow.

SEE: A Look At Corporate Profit Margins

The Bottom Line
All in all, then, the Agilent thesis is similar to what it has been for a couple of quarters now - the stock is undervalued on a long-term basis, but has enough short-term challenges that the stock may be hard-pressed to outperform. High single-digit free cash flow growth should be attainable, and if the company can do so these shares ought to trade closer to $50.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  2. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  3. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  4. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  5. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  6. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
  7. Stock Analysis

    The Safest Stocks You Can Invest in Right Now

    These stocks are likely to hold up better than others in a bear market, but there's a twist.
  8. Investing Basics

    5 Reasons to Expect Lower Stock Returns

    Lower stock returns are likely here to stay for some time. Here are five reasons why.
  9. Investing Basics

    What to Cut From Your Portfolio Right Now

    Owning stocks may shortly become too scary for your portfolio. Here's why, and here are some alternatives.
  10. Personal Finance

    Careers: Equity Research Vs. Investment Banking

    Equity research is sometimes viewed as the unglamorous, lower-paid cousin to investment banking. In this article, we compare the two careers.
RELATED TERMS
  1. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  2. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  3. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!